✓ Translated by DotMD AI Clinical Council Source: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #38431112 ↗

Randomized Controlled Trial: Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA) (N = 75)

Original Paper Title: “Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 75
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Compared to guideline-recommended high-intensity statin therapy, moderate-intensity statin with ezetimibe further improved the achievement rate of LDL-C in patients with acute ischemic cerebrovascular disease, with a higher reduction magnitude in LDL-C.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (N = 75 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2024), this randomized controlled trial evaluating 75 human participants investigated: High-risk stroke patients are recommended to receive high-intensity statin therapy to reduce the risk of stroke recurrence. Key clinical takeaway: Compared to guideline-recommended high-intensity statin therapy, moderate-intensity statin with ezetimibe further improved the achievement rate of LDL-C in patients with acute ischemic cerebrovascular disease, with a higher reduction magnitude in LDL-C.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2024-05-15; N = 75; Rigor 82/100): Compared to guideline-recommended high-intensity statin therapy, moderate-intensity statin with ezetimibe further improved the achievement rate of LDL-C in patients with acute ischemic cerebrovascular disease, with a higher reduction magnitude in LDL-C.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: ezetimibe → Rx: ezetimibe-and-simvastatin → Rx: rosuvastatin-calcium → Rx: rosuvastatin → Condition: cholesterol → Condition: stroke →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38431112: Randomized Controlled Trial: Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA) (N = 75)

3 of 3 Free Questions Remaining